0 CHECKOUT

PRODUCT FILTERS

REGION

30
26
24
22
15

COUNTRY

13
9
9
6

CATEGORIES

  • 89
  • 7
  • 7
  • 4
  • 4
  • 2
  • 2
  • 2
  • 2
  • 2
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1

PRICE

47
99
105
125

PUBLISHED

1
5
22
125

PRODUCT TYPE

114
7
2
1
1

Search for: "Outcome Measures in Alzheimer's Disease"

Alzheimer'S Disease: Pharmacuetical Drugs Vs. Medicinal Plants - Markets, Competitors and Opportunities: 2015-2020 Analysis and Forecasts

The objective of this report is to provide a detailed analysis of Alzheimer’s disease (AD) and the pharmaceutical drugs and medicinal plants used to treat and prevent it. It also provides an overview...

Published:  July 2015
Price:  From

Alzheimer's Disease - Pipeline Review, H2 2015

Alzheimer's Disease - Pipeline Review, H2 2015 Summary The report ‘Alzheimer's Disease - Pipeline Review, H2 2015’, provides an overview of the Alzheimer's Disease’s therapeutic pipeline. This report...

Published:  December 2015
Price:  From

Alzheimer's Disease - Pipeline Review, H1 2015

Alzheimer's Disease - Pipeline Review, H1 2015 Summary This, ‘Alzheimer's Disease - Pipeline Review, H1 2015’, provides an overview of the Alzheimer's Disease’s therapeutic pipeline. This report...

Published:  January 2015
Price:  From

Endpoints - Clinical Trials in CNS Disorders - Multiple Endpoints and Ratings Scales are Becoming More Widely Adopted

GBI Research, the leading business intelligence provider, has released its latest research “Endpoints - Clinical Trials in CNS Disorders - Multiple Endpoints and Ratings Scales are Becoming More Widely...

Published:  November 2011
Price:  From

Alzheimer's Disease – Pipeline Review, H1 2013

Global Markets Direct's, 'Alzheimer's Disease - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline This report provides information on the therapeutic development...

Published:  February 2013
Price:  From

Targacept’s TC-5619 - The prospects for this fully-owned alpha-7 neuronal nicotinic receptor agonist

Earlier this year, Targacept reported that its phase II proof of concept study of TC-5619 in cognitive dysfunction in schizophrenia (CDS) met the pre-specified primary endpoint, while the trial in ADHD...

Published:  May 2011
Price:  From

Neuroprotection - Drugs, Markets and Companies

This report describes the role of neuroprotection in acute disorders such as stroke and injuries of the nervous system as well as in chronic diseases such as neurodegenerative disorders because many...

Published:  January 2016
Price:  From

Global Clinical Trials for Alzheimer's Disease

Global Clinical Trials for Alzheimer's Disease is a handy one-stop reference for researchers and physicians planning and conducting global clinical trials in this area. This book addresses important...

Published:  November 2013
Price: 

Alzheimer's Disease - Pipeline Review, Q4 2010

Alzheimer's Disease - Pipeline Review, Q4 2010 Summary Global Markets Direct’s, “Alzheimer's Disease Pipeline Review, Q4 2010”, provides an overview of the Alzheimer's Disease therapeutic pipeline....

Published:  December 2010
Price:  From

Biomarkers - Technologies, Markets and Companies

This report follows the broad definition of a biomarker as a characteristic that can be objectively measured and evaluated as an indicator of normal biological or pathogenic processes as well as pharmacological...

Published:  January 2016
Price:  From

Alzheimer's Disease - Pipeline Review, Q1 2011

Alzheimer's Disease - Pipeline Review, Q1 2011 Summary Global Markets Direct’s, 'Alzheimer's Disease - Pipeline Review, Q1 2011', provides an overview of the Alzheimer's Disease therapeutic pipeline....

Published:  February 2011
Price:  From

Biomarkers in Drug Discovery - Integration in Early Stage Promotes Use of Companion Diagnostics to Optimize Therapeutic Outcomes

GBI Research’s new report, “Biomarkers in Drug Discovery - Integration in Early Stage Promotes Use of Companion Diagnostics to Optimize Therapeutic Outcomes” provides information and analysis on the...

Published:  November 2012
Price:  From

Global Pharmaceutical & Biotechnology Outlook 2013: Global Pharma

Global Pharmaceutical & Biotechnology Outlook 2013: Global Pharma Over the next five years, we will witness surge in approval of new drugs that would deliver a major improvement in the standard of care...

Published:  January 2013
Price:  From

Top R&D Drug Failures - Toxicity and Serious Adverse Events in Late Stage Drug Development are the Major Causes of Drug Failure

‘Top R&D Drug Failures - Toxicity and Serious Adverse Events in Late Stage Drug Development are the Major Causes of Drug Failure’ provides insights into major drug failures during 2005–2010 The 20 drugs...

Published:  July 2011
Price:  From

The 2016-2021 Outlook for Drugs for Alzheimer's and Parkinson's Diseases in India

WHAT IS LATENT DEMAND AND THE P.I.E.? The concept of latent demand is rather subtle. The term latent typically refers to something that is dormant, not observable, or not yet realized. Demand is...

Published:  September 2015
Price: 

The 2016-2021 Outlook for Drugs for Alzheimer's and Parkinson's Diseases in Greater China

WHAT IS LATENT DEMAND AND THE P.I.E.? The concept of latent demand is rather subtle. The term latent typically refers to something that is dormant, not observable, or not yet realized. Demand is...

Published:  September 2015
Price: 

Molecular Diagnostics - Technologies, Markets and Companies

This report describes and evaluates the molecular diagnostics technologies that will play an important role in practice of medicine, public health, pharmaceutical industry, forensics and biological...

Published:  January 2016
Price:  From

Commercializing Biomarkers in Therapeutic and Diagnostic Applications

Biomarkers feature in thousands of published articles each year, evidencing the high level of interest and research in this field. This report focuses on issues that must be addressed to utilize this...

Published:  May 2011
Price:  From

Emerging Medical Technologies Spotlight

Emerging Medical Technologies (EMT) Spotlight ® is a resource for strategic marketing, market research, business development, and investment executives seeking discreet and detailed business, market,...

Published:  February 2016
Price: 

Global Biopharma Outlook 2011: Major US and EU

The year 2011 and 2012 will be a bonanza for generic companies, as large innovator companies will lose patent exclusivity on prescription drugs worth over $70b in sales It is imperative to understand...

Published:  February 2011
Price:  From
Loading Indicator

Our Clients

  • Procter & Gamble Co.
  • Western Union Company
  • Volvo Car Corporation
  • Morgan Stanley
  • SAP SE
  • LG Corporation
  • Roche Diagnostics Ltd.